Le Lézard
Classified in: Health
Subjects: WOM, FDA

JayMac Pharmaceuticals' EnBrace HRtm Clinical Study Finds Rx Prenatal Vitamin Treats and Prevents Depression in Women Before and During Pregnancy


LAFAYETTE, La., Feb. 26, 2019 /PRNewswire/ -- Women who struggle with depression during and around the time of pregnancy frequently opt to discontinue the use of antidepressants due to the possible risks to the fetus, putting themselves at jeopardy for depression relapse. Outcomes from the newly released Massachusetts General Hospital (MGH)/Harvard pilot clinical trial of JayMac Pharmaceuticals' EnBrace HRtm for the treatment of women seeking antidepressant alternatives for Major Depressive Disorder (MDD) in anticipation of or during pregnancy verify that EnBrace HR is an effective alternative. Women wanting to discontinue or minimize the use of antidepressants no longer need to choose between the safety of their baby and treatment of their depression.

The efficacy observed in this study confirms that Rx EnBrace HR, an all-natural, nutritional prenatal vitamin with methylfolate, is an effective, safe option for treating and preventing depression in pregnancy and was well tolerated by patients. The findings from the clinical trial were published online this month in Annals of Clinical Psychiatry.

In this study, EnBrace HR was investigated for depressive relapse prevention and for acute treatment of MDD in women planning pregnancy or during pregnancy. The study notes there is an evidence base for the antidepressant effects of the shared interconversion of folic acid, folinic acid and methylfolate, as found in EnBrace HR, showing significant improvement in perinatal depressive symptoms and providing a new treatment option for depression in pregnancy. Perinatal depression has been a critical public health concern and therapeutic dilemma for practitioners for years.

MGH Center for Women's Mental Health states in its February 6, 2019 blog post that, "This pilot study suggests that EnBrace HR may be helpful for not only for preventing depressive relapse during pregnancy but may also have antidepressant effects....  While this was a small study, these results are exciting and we look forward to seeing more studies with EnBrace HR and similar compounds for women who are at risk for depression during pregnancy."

JayMac Pharmaceuticals develops natural, evidence-based, root-cause treatments for psychiatric disorders that address genetic insufficiencies. Follow this link for the complete release (PDF). For additional information, visit http://www.enbracehr.com/ or call 985-788-7755.

Media Contact:
Laura Luthi
210015@email4pr.com
503.341.7785

 

SOURCE EnBrace HR


These press releases may also interest you

at 17:50
Amphivena Therapeutics, Inc., a private clinical stage immuno-oncology company developing T cell engager therapeutics for cancer, presented today at the American Society of Hematology annual meeting data from a Phase 1 study of its bivalent T cell...

at 17:40
Welltower Inc. announces that on December 24, 2019, it is redeeming all of the outstanding 3.35% Senior Notes due November 25, 2020 (the "Notes") issued by HCN Canadian Holdings-1 LP, its wholly-owned subsidiary, in accordance with the terms of the...

at 17:20
Quest Diagnostics Incorporated , the world's leading provider of diagnostic information services, announced today the pricing of a public offering of $800 million aggregate principal amount of its 2.950% senior notes due 2030 under the Quest...

at 17:20
Bariatric Surgery Devices (General Surgery) - Global Market Analysis and Forecast Model Read the full report: https://www.reportlinker.com/p05830908/?utm_source=PRN Summary Bariatric Surgery Devices (General Surgery) - Global Market Analysis and...

at 17:19
Florida International University Distinguished Professor Madhavan Nair has been named a Fellow of the National Academy of Inventors (NAI). Nair, an internationally renowned expert in nanotechnology and HIV research, is the founding chair of the...

at 17:05
TFF Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced its third quarter 2019...



News published on 26 february 2019 at 08:45 and distributed by: